Cargando…

Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder

Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently publi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazary, Judit, Elemery, Monika, Dome, Peter, Kiss, Szilvia, Gonda, Xenia, Tombor, Laszlo, Pogany, Laszlo, Becskereki, Gergely, Toth, Blanka, Faludi, Gabor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065048/
https://www.ncbi.nlm.nih.gov/pubmed/33893327
http://dx.doi.org/10.1038/s41598-021-87840-5
_version_ 1783682260721991680
author Lazary, Judit
Elemery, Monika
Dome, Peter
Kiss, Szilvia
Gonda, Xenia
Tombor, Laszlo
Pogany, Laszlo
Becskereki, Gergely
Toth, Blanka
Faludi, Gabor
author_facet Lazary, Judit
Elemery, Monika
Dome, Peter
Kiss, Szilvia
Gonda, Xenia
Tombor, Laszlo
Pogany, Laszlo
Becskereki, Gergely
Toth, Blanka
Faludi, Gabor
author_sort Lazary, Judit
collection PubMed
description Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently published animal data implicated relevant associations with changes in endocannabinoid (eCB) brain levels during rTMS treatment, human studies, however, have not been published. In our study we assessed the detailed phenotypic spectrum of MDD and serum 2-arachidnoylglycerol (2-AG) and anandamide (AEA) levels in 18 patients with treatment-resistant depression before, immediately following, and two weeks after completion of a 10-day rTMS treatment. We found significant associations between serum 2-AG level changes from pretreatment to 2 weeks after treatment and symptom reduction. The greater the increase of 2-AG levels, the greater the improvement of depressive (p = 0.031), anxious (p = 0.007) and anhedonia symptoms (p = 0.047). Here we report for the first time a significant association of human circulating eCB and antidepressant effect of rTMS. Our data may indicate that direct stimulation of targeted brain areas can rapidly alleviate depressive complaints via activation of the eCB system.
format Online
Article
Text
id pubmed-8065048
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80650482021-04-27 Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder Lazary, Judit Elemery, Monika Dome, Peter Kiss, Szilvia Gonda, Xenia Tombor, Laszlo Pogany, Laszlo Becskereki, Gergely Toth, Blanka Faludi, Gabor Sci Rep Article Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently published animal data implicated relevant associations with changes in endocannabinoid (eCB) brain levels during rTMS treatment, human studies, however, have not been published. In our study we assessed the detailed phenotypic spectrum of MDD and serum 2-arachidnoylglycerol (2-AG) and anandamide (AEA) levels in 18 patients with treatment-resistant depression before, immediately following, and two weeks after completion of a 10-day rTMS treatment. We found significant associations between serum 2-AG level changes from pretreatment to 2 weeks after treatment and symptom reduction. The greater the increase of 2-AG levels, the greater the improvement of depressive (p = 0.031), anxious (p = 0.007) and anhedonia symptoms (p = 0.047). Here we report for the first time a significant association of human circulating eCB and antidepressant effect of rTMS. Our data may indicate that direct stimulation of targeted brain areas can rapidly alleviate depressive complaints via activation of the eCB system. Nature Publishing Group UK 2021-04-23 /pmc/articles/PMC8065048/ /pubmed/33893327 http://dx.doi.org/10.1038/s41598-021-87840-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lazary, Judit
Elemery, Monika
Dome, Peter
Kiss, Szilvia
Gonda, Xenia
Tombor, Laszlo
Pogany, Laszlo
Becskereki, Gergely
Toth, Blanka
Faludi, Gabor
Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_full Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_fullStr Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_full_unstemmed Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_short Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_sort peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rtms) treatment in patients with major depressive disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065048/
https://www.ncbi.nlm.nih.gov/pubmed/33893327
http://dx.doi.org/10.1038/s41598-021-87840-5
work_keys_str_mv AT lazaryjudit peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT elemerymonika peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT domepeter peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT kissszilvia peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT gondaxenia peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT tomborlaszlo peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT poganylaszlo peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT becskerekigergely peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT tothblanka peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
AT faludigabor peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder